Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04259346 · ClinicalTrials.gov registry record · Phase 1
A Study of Two Formulations of Ixekizumab in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 245
- Enrollment target
NCT04259346: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT04259346 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 245 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (308% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04259346, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 245 participants
- Enrollment target
Study Summary
The purpose of this study is to compare two different formulations of ixekizumab. One formulation (Reference) is approved by the Food and Drug Administration (FDA) and one formulation (Test) is not approved. This study will compare how much of each formulation gets into the blood stream. Information about any side effects that may occur will also be collected. The study will last up to about four months for each participant.
Primary Outcome
PK: Cmax of ixekizumab was evaluated
Interventions
- DRUG Ixekizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2020-02-05 |
| Est. Completion | 2021-02-19 |
| Phase | Phase 1 |
What the finished NCT04259346 record still lists
NCT04259346 is an interventional study that assigns participants to a tested intervention. The registered 245 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (308% higher).
The record links to 0 conditions, and to 1 intervention - of which Ixekizumab is the first listed.
NCT04259346 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04259346 about?
NCT04259346 is a clinical study titled "A Study of Two Formulations of Ixekizumab in Healthy Participants". The purpose of this study is to compare two different formulations of ixekizumab. One formulation (Reference) is approved by the Food and Drug Administration (FDA) and one formulation (Test) is not approved. This study will compare how much of each formulation gets into the blood stream. Information...
What is the current status of trial NCT04259346?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 245 participants. The study started on 2020-02-05. Estimated completion is 2021-02-19.
What interventions are being tested in trial NCT04259346?
The interventions under investigation include: Ixekizumab (DRUG).
Who is sponsoring clinical trial NCT04259346?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04259346's enrollment target sits among peer trials
245 189th of 2000 higher than 1,810 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03645928 · 245 participants · Phase 2
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- NCT04718168 · 245 participants · NA
GORE® ENFORM Biomaterial Product Study
- NCT05145127 · 245 participants · Phase 3
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- NCT05446259 · 245 participants
Degenerative Cervical Myelopathy Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI